Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367340 | 0.89 | CHRM1 (0.36) | MAPK1ATMCHRM1CA12CA1 | |
| SCHEMBL15607811 | 0.84 | EGFR (0.36) | MAPK1ATMCHRM1CA12CA1 | |
| SCHEMBL16367302 | 0.82 | POLB (0.36) | MAPK1ATMCA12CA1CA2 | |
| SCHEMBL16367308 | 0.81 | ALDH1A1 (0.31) | MAPK1ATMALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL16367384 | 0.80 | MAPK1 (0.40) | MAPK1ATMCHRM1ALDH1A1RAB9A | |
| SCHEMBL15607837 | 0.79 | TK1 (0.32) | MAPK1ATM | |
| SCHEMBL15607866 | 0.79 | MAPK1 (0.38) | MAPK1ATMCHRM1ALDH1A1RAB9A | |
| SCHEMBL16367322 | 0.79 | MAPK1 (0.38) | MAPK1ATMCHRM1ALDH1A1RAB9A | |
| SCHEMBL16367351 | 0.79 | MAPK1 (0.38) | MAPK1ATMCHRM1ALDH1A1RAB9A | |
| SCHEMBL16367326 | 0.77 | MAPK1 (0.61) | MAPK1ATMCHRM1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | MAPK1 3155/4885ATM 4802/4885CHRM1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.